ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0954

Non-canonical WNTA Promotes Cytoskeletal Rearrangement and Integrin Alpha V Clustering via JNK and ROCK to Control the Activation of Latent TGFβ

Thuong Trinh-Minh1, Chih-Wei Chen2, Cuong Tran Manh1, yi-nan Li1, Honglin Zhu3, Debomita Chakraborty4, Yun Zhang1, Simon Rauber5, Clara Dees5, Christina Bergmann6, Alexander Kreuter7, Christiane Reuter8, Florian Groeber-Becker8, Beate Eckes9, Oliver Distler10, Andreas Ramming11, Georg Schett12 and Joerg Distler1, 1Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, 23 Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany. 4 Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, 33 Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany. 4 Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany. 5 Department of Rheumatology, Xiangya Hospital, Central South University, Changsha, China, 43 Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany. 4 Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 53 Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany. 4 Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, 6Department Internal Medicine, University Hospital Erlangen, Germany, Erlangen, Germany, 7Clinic for Dermatology, Venereology and Allergology, HELIOS St. Elisabeth Clinic, Oberhausen, Germany, 8Translational Center for Regenerative Therapies, Fraunhofer Institute for Silicate Research (ISC) Würzburg, Würzburg, Germany, 9Translational Matrix Biology, University of Cologne, Cologne, Germany. 9 Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Köln, Germany, 10Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 11Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany; Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 12Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

Meeting: ACR Convergence 2023

Keywords: Collagen, Fibroblasts, Dermal, Scleroderma, Systemic sclerosis, Transforming Growth Factor (TGF)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (0934–0964) Systemic Sclerosis & Related Disorders – Basic Science Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disorder with vasculopathy, inflammation, and fibrosis of the skin and organs. Fibrosis is caused by the abnormal activation of latent transforming growth factor beta (TGFβ) by fibroblasts, resulting in excessive extracellular matrix and tissue damage. WNT5A is a non-canonical WNT ligand which significantly expresses higher in fibrotic diseases. We aimed to investigate the role of WNT5A and its downstream intracellular signaling and gene expression in fibroblast activation in SSc and other fibrotic diseases. We also tested the effect of blocking WNT5A downstream targets on latent TGFβ activation and fibrosis.

Methods: We performed bulk RNA sequencing (RNAseq) of WNT5A-stimulated fibroblasts with or without pretreatment with inhibitors of potential downstream mediators of WNT5A (small molecule inhibitors against JNK, ROCK, integrin alpha V – ITGAV, TGFβR1 and actin polymerization). To confirm the findings, we treated WNT5A-overexpressing mice with those inhibitors. We quantified the active TGFβ level in vitro and in vivo by transformed mink lung epithelial cells assays. The contraction force and cellular stiffness of WNT5A-stimulated fibroblasts were analyzed by 3D microtissue assays and magnetic tweezers. Formation of focal adhesions (FAs) and cytoskeleton rearrangement were evaluated by Western blot, IF staining, and live-cell imaging.

Results: 38% of DEGs of a cohort of patients with early, diffuse-cutaneous SSc (PRESS1) matched the genes regulated by WNT5A in cultured fibroblasts. Ubiquitous knockout of WNT5A or fibroblast-specific knockout of WNT5A are protected from experimental fibrosis. RNAseq of fibroblasts treated with respective inhibitors revealed 75% of the WNT5A-regulated DEGs were regulated by JNK- and ROCK-dependent manner. Functional analysis of the DEGs indicated that WNT5A regulates TGFβ signaling, FAs, integrin activation and cytoskeleton organization. Indeed, WNT5A induced the formation of FAs with increased levels of p-Talin and p-Paxillin, ITGAV clustering and cytoskeletal rearrangement involving Vimentin, actin filaments, and microtubules. All of these changes were dependent on the activation of latent TGFβ, which was strongly induced by WNT5A in cultured fibroblasts. Pharmacological inhibition of JNK, ROCK, TGFβR1, ITGAV, or actin polymerization blocked the activation of latent TGFβ, reduced cellular stiffening, prevented integrin activation, and in particular reduced fibroblast-to-myofibroblast transition and collagen deposition in cultured fibroblasts. Moreover, Pharmacological inhibition of the downstream mediators also reduced the levels of active TGFβ and fibrotic remodeling of skin in mice overexpressing WNT5A.

Conclusion: We demonstrate that WNT5A/JNK/ROCK signaling axis regulates the activation of latent TGFβ by induction of cytoskeletal rearrangement, cellular tension forces and clustering of ITGAV. Blocking of WNT5A or its downstream pathways prevents the aberrant activation of latent TGFβ in experimental fibrosis, prevents fibroblast-to-myofibroblast transition and tissue fibrosis. Targeting of WNT5A may thus offer potential for novel antifibrotic therapies.

Supporting image 1

WNT5A induces JNK and ROCK to promote coordinated cytoskeletal remodeling that drives ITGAV-dependent activation of latent TGFβ in fibrotic disorders


Disclosures: T. Trinh-Minh: None; C. Chen: None; C. Tran Manh: None; y. Li: None; H. Zhu: None; D. Chakraborty: None; Y. Zhang: None; S. Rauber: None; C. Dees: None; C. Bergmann: Boehringer-Ingelheim, 2, 5, Janssen, 2; A. Kreuter: None; C. Reuter: None; F. Groeber-Becker: None; B. Eckes: None; O. Distler: 4P-Pharma, 2, 5, 6, AbbVie, 2, 5, 6, Acceleron, 2, 5, 6, Alcimed, 2, 5, 6, Altavant Sciences, 2, 5, 6, Amgen, 2, 5, 6, AnaMar, 2, 5, 6, Arxx, 2, 5, 6, AstraZeneca, 2, 5, 6, Bayer, 2, 5, 6, Blade Therapeutics, 2, 5, 6, Boehringer Ingelheim, 2, 5, 6, Citus AG, 12, Co-Founder, Corbus Pharmaceuticals, 2, 5, 6, CSL Behring, 2, 5, 6, Galapagos, 2, 5, 6, Galderma, 2, 5, 6, Glenmark, 2, 5, 6, Gossamer, 2, 5, 6, Horizon Therapeutics, 2, 5, 6, Janssen, 2, 5, 6, Kymera, 2, 5, 6, Lupin, 2, 5, 6, Medscape, 2, 5, 6, Miltenyi Biotec, 2, 5, 6, Mitsubishi Tanabe, 2, 5, 6, MSD, 2, 5, 6, Novartis, 2, 5, 6, Patent issued “mir-29 for the treatment of systemic sclerosis” (US8247389, EP2331143), 10, Prometheus Biosciences, 2, 5, 6, Redx Pharma, 2, 5, 6, Roivant, 2, 5, 6, Topadur, 2, 5, 6; A. Ramming: None; G. Schett: None; J. Distler: 4D Science and FibroCure, 8, 11, AbbVie, Active Biotech, Anamar, ARXX, AstraZeneca, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, Genentech, GSK, Inventiva, Janssen, Novarti, 2, Anamar, Argenx, ARXX, BMS, Bayer Pharma, Boehringer Ingelheim, Cantargia, Celgene, CSL Behring, Galapagos, GSK, 5, Inventiva, Kiniksa, Lassen, Sanofi-Aventis, RedX, UCB, 5.

To cite this abstract in AMA style:

Trinh-Minh T, Chen C, Tran Manh C, Li y, Zhu H, Chakraborty D, Zhang Y, Rauber S, Dees C, Bergmann C, Kreuter A, Reuter C, Groeber-Becker F, Eckes B, Distler O, Ramming A, Schett G, Distler J. Non-canonical WNTA Promotes Cytoskeletal Rearrangement and Integrin Alpha V Clustering via JNK and ROCK to Control the Activation of Latent TGFβ [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/non-canonical-wnta-promotes-cytoskeletal-rearrangement-and-integrin-alpha-v-clustering-via-jnk-and-rock-to-control-the-activation-of-latent-tgf%ce%b2/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/non-canonical-wnta-promotes-cytoskeletal-rearrangement-and-integrin-alpha-v-clustering-via-jnk-and-rock-to-control-the-activation-of-latent-tgf%ce%b2/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology